Oncology
Theriva Biologics S.L. is focused on clinical research in cancer, with activity centered on advanced pancreatic cancer and metastatic pancreatic cancer. Its trial portfolio reflects interest in treatment settings where disease control and survival outcomes remain major clinical needs.
- Advanced pancreatic cancer
- Metastatic pancreatic cancer
- Overall survival
The sponsor’s research activity is directed toward outcomes relevant to late-stage pancreatic malignancy, including survival and disease management in patients receiving standard therapy.
Tumour-directed therapeutic development
The company’s clinical interest extends to therapeutic innovation in pancreatic tumour care, with evaluation of investigational approaches intended to support treatment of aggressive solid tumours. Its work is concentrated in a single active disease area, indicating a highly targeted research focus.
- Solid tumour therapy
- Pancreatic tumour treatment
- Investigational oncology agents
Current research activity is aligned with clinical needs in difficult-to-treat pancreatic cancer, where therapeutic options are limited and outcomes are poor.
Safety and tolerability
Another key area of interest is the assessment of safety and tolerability in patients with advanced pancreatic cancer. The sponsor’s trial portfolio includes monitoring of treatment-related effects alongside efficacy-related endpoints.
- Safety evaluation
- Tolerability assessment
- Patient treatment burden
This therapeutic emphasis is especially relevant in metastatic disease, where treatment-related risk and clinical fragility are important considerations.
Clinical collaboration in oncology
Theriva Biologics S.L. conducts its research through a network of collaborating sites in Spain, supporting clinical activity in a concentrated oncology setting. The sponsor’s funded research remains limited in scope but is clearly directed toward a defined therapeutic domain.
- Collaborating research sites
- Spain-based clinical activity
- Pancreatic cancer research network
The clinical landscape is shaped by a single ongoing study in oncology, with emphasis on patient outcomes in advanced pancreatic cancer.
